Results 141 to 150 of about 17,145 (193)

A multi-centre randomised controlled trial comparing megestrol acetate to levonorgestrel-intrauterine system in fertility sparing treatment of atypical endometrial hyperplasia. [PDF]

J Assist Reprod Genet
Goh CSY, Loh MJM, Lim WW, Ang JX, Nadarajah R, Yong TT, Tong P, Yeo YC, Phoon JWL.   +8 more
europepmc   +1 more source

The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis. [PDF]

Reprod Biol Endocrinol
Zhang B, Shi J, Gu Z, Wu Y, Li X, Zhang C, Yan H, Li Q, Lyu S, Dai Y, Leng J.   +10 more
europepmc   +1 more source

Personal and work-related factors that impact the decision to have the first and recurrent abortion among women in Serbia. [PDF]

Libyan J Med
Gazibara T, Maksimovic N, Maksimovic J, Tulic L, Bila J, Stojnic J, Miloradovic M, Plavsa D, Radovic M, Maksimovic K, Dotlic J.   +10 more
europepmc   +1 more source

The use of LNG-IUS-19.5 mg in daily gynecological routine practice in Germany: data from the Kyleena™ Satisfaction Study (KYSS). [PDF]

Arch Gynecol Obstet
Römer T, Frenz AK, Dietrich-Ott S, Fiedler A.   +3 more
europepmc   +1 more source

Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system. [PDF]

PLoS One
Lopes da Silva Filho A, Luis Pereira Bueno R, Ramires Y, Lino LMC.   +3 more
europepmc   +1 more source

Cost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial. [PDF]

BMJ Open
Melyda M, Monahan M, Cooper KG, Bhattacharya S, Daniels JP, Cheed V, Middleton L, Roberts TE.   +7 more
europepmc   +1 more source

Moderate Associations Between the Use of Levonorgestrel-releasing Intrauterine Device and Metabolomics Profile.

J Clin Endocrinol Metab
Toffol E, Heikinheimo O, Jousilahti P, Lehtoranta L, Joensuu A, Partonen T, Erlund I, Haukka J.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Intrauterine Devices: Medicated and Nonmedicated

International Journal of Gynecology & Obstetrics, 1979
The main benefits of intrauterine devices (IUDs) are a lack of adverse systemic effects, excellent effectiveness, high continuation rates and the single act of motivation required for use. First year failure rates range from 2% to 3%, but decline steadily thereafter to a cumulative annual failure rate of less than 1% after six years.
D. Mishell
openaire   +3 more sources